Vallon Pharmaceuticals

Vallon Pharmaceuticals is a privately-held, clinical-stage pharmaceutical company based in Philadelphia, dedicated to developing new drugs to help patients with central nervous system (CNS) disorders. The company's lead investigational product candidate is ADAIR, an abuse-deterrent formulation designed to prevent the immediate release of amphetamines, for the treatment of ADHD and narcolepsy.